REXGENERO is a late-stage regenerative medicine company developing advanced cell-based therapeutics for the treatment of critical limb ischemia (CLI), a large global market with high unmet medical need
Cellular Therapies have the potential to successfully treat serious vascular, neurological and other disorders. Rexgenero’s technologies engineer naturally occurring stem cells to regenerate diseased tissues.
In our clinical programs we are investigating the effectiveness of our therapies in diabetic and non-diabetic patients with peripheral arterial disease and associated critical limb ischemia.
Our clinical candidate therapies use three different stem cell technologies: